Intelligent Bio Q3 revenue $1.06M (+46% YoY); cartridge sales up 59%

INTELLIGENT BIO SOLUTIONS INC.

2026-Q3 EPS reported -$7.54 revenue$3,069,373

Q3 cartridge revenue $703,538, up 59% YoY, representing 66% of total sales.
Gross profit margin expanded to 50.5% in Q3 (vs 46.8% prior year); nine-month margin 49.3%.
Nine-month revenue reached $3.07M, up 39% YoY; cash balance $6.86M at March 31, 2026.
Marketing spend in Q3 down 42% YoY while commercial momentum accelerated.
FDA 510(k) program advancing; new manufacturing partnership and Bouygues UK customer added.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTELLIGENT BIO SOLUTIONS INC. reported the fiscal third quarter and nine months ended March 31, 2026 results: revenue Total revenue of $1.06 million, up 46% year-over-year.

Period: the fiscal third quarter and nine months ended March 31, 2026
Revenue: Total revenue of $1.06 million, up 46% year-over-year
Result: reported results

Exact text from the filing

except as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Intelligent Bio Solutions Reports Fiscal Third Quarter Revenue Growth of 46% Year-over-Year Razor-razorblade business model accelerates, with Q3 cartridge revenue up 59% year-over-year, representing 66% of quarterly sales Nine-month revenue reaches $3.07

View on SEC.gov

Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-022823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.